Results 121 to 130 of about 21,372 (208)

A guide to transcriptional cyclin‐dependent kinases in cancer

The FEBS Journal, EarlyView.
Transcriptional cyclin‐dependent‐kinases (tCDKs) facilitate gene expression by promoting RNA polymerase II (RNAPII) progression through discrete phases of the transcription cycle. Aberrant tCDK activity is detectable in different human cancers, thereby contributing to de‐regulated gene expression programs that drive oncogenic phenotypes.
Jennifer R. Devlin, Salla Kyheröinen, Ricky W. Johnstone   +2 more
wiley   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, Volume 20, Issue 10, Page 2424-2448, October 2026.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Inhibition of NRF2 enhances the acute myeloid leukemia cell death induced by venetoclax via the ferroptosis pathway

Cell Death Discovery
Venetoclax, an inhibitor that selectively targets B cell lymphoma-2 (BCL-2) that has been approved for treating adult acute myeloid leukemia (AML) in combination with hypomethylating agents.
Xibao Yu, Yan Wang, Jiaxiong Tan, Yuchen Li, Pengyue Yang, Xuan Liu, Jing Lai, Yue Zhang, Letong Cai, Yinfeng Gu, Ling Xu, Yangqiu Li   +11 more
doaj   +1 more source

Two Blastic Plasmacytoid Dendritic Cell Neoplasms treated with the CD123‐targeted agent Tagraxofusp presenting divergent outcomes

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Sven C. Engler, Elisabeth M. Walde, Edgar Jost, Amir S. Yazdi, David Kluwig   +4 more
wiley   +1 more source

Toward Predictable Nanomedicine: Current Forecasting Frameworks for Nanoparticle–Biology Interactions

Advanced Intelligent Discovery, Volume 2, Issue 5, October 2026.
Predictive models successfully screen nanoparticles for toxicity and cellular uptake. Yet, complex biological dynamics and sparse, nonstandardized data limit their accuracy. The field urgently needs integrated artificial intelligence/machine learning, systems biology, and open‐access data protocols to bridge the gap between materials science and safe ...
Mariya L. Ivanova, Michael Nicholls, Nicola Russo, Gueorgui Mihaylov, Konstantin Nikolic   +4 more
wiley   +1 more source

Venetoclax Plus Gilteritinib for

, 2022
The FMS-related tyrosine kinase 3 (FLT3) inhibitor gilteritinib is standard therapy for relapsed/refractoryThis phase Ib open-label, dose-escalation/dose-expansion study (ClinicalTrials.gov identifier: NCT03625505) enrolled patients withSixty-one ...
Wang, Jing, Siddani, Satya, Altman, Jessica K, Smith, Catherine C, Bradley, Terrence, Lee, Paul, Levis, Mark, Litzow, Mark, Ritchie, Ellen, Chyla, Brenda, Brackman, Deanna, Maly, Joseph, Perl, Alexander E, Naqvi, Kiran, Schiller, Gary, McCloskey, James, Daver, Naval, Dail, Monique, Tiu, Ramon V   +18 more
core  

Quantitation of Cirtuvivint (SM08502) in Human Plasma by LC–MS/MS

Biomedical Chromatography, Volume 40, Issue 10, October 2026.
ABSTRACT CDC‐like kinases (CLK) and dual‐specificity tyrosine‐regulated kinases (DYRK) are protein kinases involved in various cellular functions, mRNA splicing, and DNA damage repair. CLK/DYRK kinases have been implicated in many disorders such as diabetes, neurodegenerative diseases, and cancer.
Julianne L. Holleran, Joshua J. Deppas, Ye Feng, Michael J. Hochman, Evan C. Chen, Maximilian Stahl, Steven D. Gore, Timothy W. Synold, Jan H. Beumer, Raman Venkataramanan, Robert A. Parise   +10 more
wiley   +1 more source

Outcomes of adult patients with Li‐Fraumeni syndrome and myeloid neoplasms

Cancer, Volume 132, Issue 19, 1 October 2026.
Abstract Background Li‐Fraumeni syndrome (LFS) is an inherited cancer predisposition syndrome. Hematologic malignancies are not considered LFS defining tumors, however, both acute lymphoblastic leukemia and therapy‐related myeloid neoplasms (MNs) in LFS are described. Treatment approaches and outcomes of MN in LFS need further evaluation.
Jayastu Senapati, Hiam M. Abdel‐Salam, Vladislav D. Jdanov, Sanam Loghavi, Ashley Woodson, Jessica Corredor, Gautam Borthakur, Naval G. Daver, Tapan M. Kadia, Koichi Takahashi, Yesid Alvarado, Naveen Pemmaraju, Uday R. Popat, Elizabeth J. Shpall, Farhad Ravandi, Florencia McAllister, Najat C. Daw, Guillermo Garcia‐Manero, Banu K. Arun, Courtney D. DiNardo   +19 more
wiley   +1 more source

Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc‐fusion protein SL‐172154 (SIRPα‐Fc‐CD40L) in patients with higher‐risk myelodysplastic syndrome or acute myeloid leukemia

Cancer, Volume 132, Issue 19, 1 October 2026.
Abstract Background This clinical trial sought to determine whether SL‐172154 could be combined safely and improve the efficacy of azacitidine (AZA) in patients with higher‐risk myelodysplastic syndrome (HR‐MDS) or acute myeloid leukemia (AML). Methods Dose escalation: doses of 1, 3, and 6 mg/kg SL‐172154 was evaluated as monotherapy or in combination ...
Naval G. Daver, Amer M. Zeidan, Anthony S. Stein, Joshua F. Zeidner, Keri Maher, Emily Curran, Dale Bixby, Wanxing Chai‐Ho, Maximilian Stahl, Karen W. L. Yee, Don Stevens, Sawa Ito, Jana Reynolds, Patrick Medd, Emma Searle, Andrew Sochacki, Mary Lynn Savoie, Steven Green, Kazunobu Kato, Robert Hernandez, Simon Metenou, Bo Ma, Lini Pandite, Taylor H. Schreiber, David A. Sallman   +24 more
wiley   +1 more source

One cycle of nelarabine given after induction is well tolerated but does not improve outcome in adults with T‐cell precursor acute lymphoblastic leukemia: Outcome data from the UKALL14 randomized‐controlled trial

HemaSphere, Volume 10, Issue 10, October 2026.
Abstract UKALL14 (NCT01085617) T‐cell arm was a phase 3, randomized‐controlled trial. Adults aged 25–65 years were randomized 1:1 at entry to receive standard of care (SOC) or SOC + nelarabine 1.5 g/m2 (Days 1, 3, and 5) to be administered following second induction. The primary end‐point was event‐free survival (EFS).
Clare J. Rowntree, Amy A. Kirkwood, Nadine Farah, Emma Lawrie, David I. Marks, Andrew K. McMillan, Tobias F. Menne, Anthony V. Moorman, Bela Patel, Pip Patrick, Paul Smith, Krisztina Z. Alapi, Lingyi Wang, Marc R. Mansour, Adele K. Fielding   +14 more
wiley   +1 more source